Can-Fite Subsidiary OphthaliX Announces Phase III Study with CF101 for Dry Eye Syndrome did Not Meet Primary Efficacy Endpoint

Loading...
Loading...
Can-Fite BioPharma (NYSE MKT:
CANF
) announced today that its subsidiary OphthaliX Inc.
OPLI
released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist. The patients were randomized to receive two oral doses of CF101 (0.1 mg or 1.0 mg) or a placebo, for a period of 24 weeks. In the study, CF101 did not meet the primary efficacy endpoint of complete clearing of corneal staining, nor the secondary efficacy endpoints. Nonetheless, CF101 was found to be well tolerated.
See full press release
Posted In: NewsGuidanceFDAManagementGlobal
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...